01848nas a2200289   4500000000100000008004100001260001700042653000900059653004400068653001200112653002200124653001100146653001100157653002100168653001600189653003100205653003500236653001100271100001500282700001300297700001200310245007700322300000900399490000700408520112900415022001401544       2001                            d  c2001 Jan-Feb10aAged10aAnti-Inflammatory Agents, Non-Steroidal10aDapsone10aFacial Dermatoses10aFemale10aHumans10aImmunoglobulin A10aPatch Tests10aPhotosensitivity Disorders10aSkin Diseases, Vesiculobullous10aThorax1 aStöckel S1 aMeurer M1 aWozel G00aDapsone-induced photodermatitis in a patient with linear IgA dermatosis.  a50-30 v113 a<p>Dapsone (4, 4' diaminodiphenylsulfone) is an efficient antiinflammatory agent. Its therapeutic use may result in a variety of adverse effects. The most frequent unwanted reactions are hemolytic anemia and methemoglobinemia. By oral route dapsone is mainly metabolized to monoacetyldapsone (MADDS) and hydroxylamine dapsone (DDS-NOH). We report a 76-year-old female patient with linear IgA dermatosis who developed a dapsone-induced photosensitivity 8 weeks after initiation of sulfone therapy. She showed a widespread erythematous eruption in UV-exposed skin area. After clearing of skin lesions the photopatch test revealed positive reactions to dapsone, MADDS and DDS-NOH. Dapsone-induced photosensitivity to date has been described only in leprosy patients. We demonstrate for the first time that this adverse reaction is not restricted to leprosy and that dapsone metabolites may also contribute to the mechanism of photosensitivity like the parent sulfone. Dapsone-induced photosensitivity is a rare, not dose-related adverse effect of the sulfone and can also occur in patients with inflammatory skin disorders.</p>  a1167-1122